MALAT1 and myeloid sarcoma: Collectively, our study provides evidence that serum levels of MALAT1 and lnc-DC may have great clinical value as accurately promising candidate biomarkers in MS preliminary screening, these lncRNAs may play a role in the pathogenesis of MS disease.